SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects

European Respiratory Journal

Volumn 35, Issue 3, 2010, Pages 564-570

  Holz, O ^a   Khalilieh, S ^b   Ludwig Sengpiel, A ^a   Watz, H ^a   Stryszak, P ^b   Soni, P ^b   Tsai, M ^b   Sadeh, J ^b   Magnussen, H ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anti inflammatory; Chronic obstructive pulmonary disease; Interleukin 8; Myeloperoxidase; Pharmacodynamics

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR2; INTERLEUKIN 8; MYELOPEROXIDASE; OZONE; PLACEBO; PREDNISOLONE; SCH 527123; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE ACTIVATION; MALE; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NEUTROPHILIA; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SPUTUM;

ADULT; BENZAMIDES; CROSS-OVER STUDIES; CYCLOBUTANES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-8; LEUKOCYTE COUNT; LUNG; MALE; MIDDLE AGED; NEUTROPHIL INFILTRATION; NEUTROPHILS; PEROXIDASE; RECEPTORS, INTERLEUKIN-8B; SPUTUM; YOUNG ADULT;

EID: 77951165310     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00048509     Document Type: Article

References (30)

1. Chapman RW, Minnicozzi M, Celly CS, et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 2007; 322: 486-493. (Pubitemid 47105794)
2. Thatcher TH, McHugh NA, Egan RW, et al. Role of CXCR2 in cigarette smoke-induced lung inflammation. Am J Physiol Lung Cell Molec Physiol 2005; 289: L322-L328. (Pubitemid 41008916)
3. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555. (Pubitemid 47403272)
4. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-a in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996; 153: 530-534. (Pubitemid 126423950)
5. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12-18.
6. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002; 121: 151S-155S.
7. Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputumneutrophils. Thorax 1996; 51: 267-271.
8. O'Donnell RA, Peebles C, Ward JA, et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004; 59: 837-842.
9. Holz O, Tal-Singer R, Kanniess F, et al. Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J Clin Pharmacol 2005; 45: 498-503.
10. Holz O, Jörres RA, Koschyk S, et al. Changes in sputum composition during sputum induction in healthy and asthmatic subjects. Clin Exp Allergy 1998; 28: 284-292.
11. Balmes JR, Chen LL, Scannell C, et al. Ozone-induced decrements in FEV1 and FVC do not correlate with measures of inflammation. Am J Respir Crit Care Med 1996; 153: 904-909.
12. Alexis NE, Lay JC, Haczku A, et al. Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers. Environ Health Perspect 2008; 116: 799-805.
13. Khalilieh S, Tsai M, de Vries D, et al. Rising single-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CXCR2, in healthy volunteers. Eur Respir J 2007; 30: Suppl. 51, 613s.
14. Khalilieh S, Tsai M, van Marle S, et al. Rising multiple-dose safety and pharmacokinetics of oral SCH 527123, a novel antagonist of CXCR2, in healthy smokers. Eur Respir J 2007; 30: Suppl. 51, 612s.
15. Jörres RA, Nowak D, Kirsten D, et al. A short protocol for methacholine provocation testing adapted to the Rosenthal-Chai dosimeter technique. Chest 1997; 111: 866-869.
16. Jörres RA, Holz O, Zachgo W, et al. The effect of repeated ozone exposures on inflammatory markers in bronchoalveolar lavage fluid andmucosal biopsies.AmJ Respir Crit Care Med 2000; 161: 1855-1861.
17. Holz O, Mücke M, Paasch K, et al. Repeated ozone exposures enhance bronchial allergen responses in subjects with rhinitis or asthma. Clin Exp Allergy 2002; 32: 681-689.
18. Pin I, Gibson PG, Kolendowicz R, et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992; 47: 25-29.
19. Holz O, Jörres RA, Timm P, et al. Ozone-induced airway inflammatory changes differ between individuals and are reproducible. Am J Respir Crit Care Med 1999; 159: 776-784.
20. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999; 160: S49-S52.
21. Adams DH, Lloyd AR. Chemokines: leucocyte recruitment and activation cytokines. Lancet 1997; 349: 490-495.
22. van Beurden WJ, Wielders PL, Scheepers PJ, et al. Superoxide production by peripheral polymorphonuclear leukocytes in patients with COPD. Respir Med 2003; 97: 401-406.
23. Nathan C. Neutrophils and immunity: challenges and opportunities. Nature Reviews Immunology 2006; 6: 173-182.
24. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967-1976. (Pubitemid 40638367)
25. Barnes PJ. Reduced histone deacetylase in COPD: clinical implications. Chest 2006; 129: 151-155.
26. Evans E, Pastino G, Mirro EJ. Preclinical safety profile of oral SCH 527123, a novel antagonist of CXCR2. Eur Respir J 2007; 30: Suppl. 51, 775s.
27. Suratt BT, Petty JM, Young SK, et al. Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. Blood 2004; 104: 565-571.
28. Martin C, Burdon PC, Bridger G, et al. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 2003; 19: 583-593.
29. Semerad CL, Liu F, Gregory AD, et al. G-CSF is an essential regulator of neutrophil trafficking from the bone marrow to the blood. Immunity 2002; 17: 413-423.
30. Mann BS, Chung KF. Blood neutrophil activation markers in severe asthma: lack of inhibition by prednisolone therapy. Respir Res 2006; 7: 59.